Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates
The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.
1. A molded particle comprising,
at least 20% of a degradable compound of Formula (3),
wherein:
R 1 and R 2 are each independently selected from the group consisting of ethyl, methyl, propyl, isopropyl, butyl, and tert-butyl;
R 3 and R 4 are each independently selected from the group consisting of —CH 2 —, —C 2 H 4 — and —C 3 H 6 —;
each Z is an acrylate group; and
n is an integer from 0 to 30;
wherein the compound degrades under physiological conditions; and
a biodegradable polymer matrix, wherein the degradable compound crosslinks the biodegradable polymer of the matrix;
wherein the molded particle is stable for more than 24 hours upon exposure to a pH of 7.4 or higher and is degradable in less than 2 hours upon exposure to a pH of 5.0 or lower.
2. The particle of claim 1 , wherein the largest dimension of the particle has a size of less than about 500 μm.
3. The particle of claim 1 , wherein the largest dimension of the particle has a size of less than about 50 μm.
4. The particle of claim 1 , further comprising a cargo component associated with the particle.
5. A pharmaceutical formulation comprising, the particle of claim 1 and a pharmaceutically acceptable carrier.
6. A method of treatment comprising administering to a patient the pharmaceutical composition of claim 5 .
7. A composition comprising a first molded particle type and a second molded particle type, wherein the matrix material of at least one particle type comprises
i. a degradable compound having the structure of Formula (3),
wherein:
R 1 and R 2 are each independently selected from the group consisting of ethyl, methyl, propyl, isopropyl, butyl, and tert-butyl;
R 3 and R 4 are each independently selected from the group consisting of —CH 2 —, —C 2 H 4 — and —C 3 H 6 —;
each Z is an acrylate group; and
n is an integer from 0 to 30;
wherein the compound degrades under physiological conditions; and
ii. a biodegradable polymer matrix, wherein the degradable compound crosslinks the biodegradable polymer of the matrix;
wherein the at least one particle type is stable for more than 24 hours upon exposure to a pH of 7.4 or higher and is degradable in less than 2 hours upon exposure to a pH of 5.0 or lower, and
wherein, the first particle type is different from the second particle type.
8. A medical device for delivering a cargo, said device comprising a particle of claim 1 .
9. The device of claim 8 , wherein said device is selected from the group consisting of a particle, stent, catheter and implant.
10. The device of claim 8 , wherein said device is degradable.
11. The particle of claim 1 , wherein said matrix comprises at least one biodegradable polymer selected from the group consisting of a polyethylene glycol, polyglycolic lactic acid, a polyester, a polyanhydride, a polyamide, a phosphorous-based polymer, a poly(cyanoacrylate), a polyurethane, a polyorthoester, a polydihydropyran, and a polyacetal and combinations thereof.
12. The particle of claim 1 , wherein the polymer is selected from the group consisting of a polyethylene glycol, polyglycolic lactic acid, polylactic acid, polyglycolic acid, poly(hydroxybutyrate), poly(ε-caprolactone), poly(β-malic acid), poly(dioxanones), poly(sebacic acid), poly(adipic acid), poly(terpthalic acid), poly(imino carbonates), polyaminoacids, a polyphosphate, a polyphosphonate, and a polyphosphazene and combinations thereof.
13. The particle of claim 1 , wherein said matrix comprises at least one biodegradable polymer selected from the group consisting of polyethylene glycol and polyglycolic lactic acid.
14. The particle of claim 1 , wherein n is an integer from 1 to 10.
15. The particle of claim 14 , wherein said degradable compound is selected from the group consisting of:
wherein, R is methyl, ethyl, or isopropyl; or combinations of said compounds.
16. The particle of claim 4 , wherein said cargo component is selected from the group consisting of biologically active materials, elemental materials, therapeutic agents, diagnostic agents, drugs, genetic materials, nucleotide sequences, amino-acid sequences, ligands, oligopeptides, proteins, vaccines, biologics, DNA, RNA, imaging agents, contrast agents, antisense agents, radiotracers, radiopharmaceuticals, and combinations thereof.
17. The particle of claim 1 , wherein said polymer matrix comprises a co-polymer.
18. The particle of claim 4 , wherein less than about 20% of said cargo is released from said particle within about 24 hours upon exposure to a pH of 7.4 or above.
19. The particle of claim 4 , wherein at least 20% of said cargo is released from said particle within about 2 hours upon exposure to a pH of 5.0 or below.
20. The particle of claim 16 , wherein said cargo component is a drug selected from one or more anticancer agents.
21. The particle of claim 4 , wherein said degradable compound is PEG-8-DIS.
22. The particle of claim 4 , wherein said particle is comprised of at least 40% of said degradable compound.
23. The particle of claim 4 , wherein said particle is comprised of at least 60% of said degradable compound.
24. The particle of claim 4 , wherein said particle is comprised of at least 80% of said degradable compound.